This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Atreca Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Atreca prognostiziert ein Gewinnwachstum at 4.3% per annum. Der Gewinn pro Aktie wird voraussichtlich wachsen um 20.7% pro Jahr.

Wichtige Informationen

4.3%

Wachstumsrate der Gewinne

20.7%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.3%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	31 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

OTCPK:BCEL - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-52	N/A	N/A	1
12/31/2025	N/A	-48	N/A	N/A	1
12/31/2024	N/A	-38	N/A	N/A	1
12/31/2023	N/A	-65	N/A	N/A	1
9/30/2023	N/A	-98	-65	-65	N/A
6/30/2023	N/A	-85	-65	-64	N/A
3/31/2023	N/A	-93	-71	-70	N/A
12/31/2022	N/A	-97	-82	-81	N/A
9/30/2022	N/A	-105	-86	-81	N/A
6/30/2022	N/A	-110	-88	-81	N/A
3/31/2022	N/A	-108	-93	-69	N/A
12/31/2021	N/A	-109	-96	-61	N/A
9/30/2021	N/A	-103	-96	-63	N/A
6/30/2021	N/A	-98	-93	-62	N/A
3/31/2021	N/A	-92	-82	-66	N/A
12/31/2020	N/A	-86	-72	-67	N/A
9/30/2020	N/A	-83	-70	-65	N/A
6/30/2020	N/A	-76	-71	-65	N/A
3/31/2020	N/A	-74	-67	-63	N/A
12/31/2019	N/A	-67	-62	-59	N/A
9/30/2019	N/A	-59	-56	-53	N/A
6/30/2019	N/A	-53	-47	-45	N/A
3/31/2019	N/A	-44	-41	-40	N/A
12/31/2018	N/A	-38	-36	-35	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: BCEL wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: BCEL wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: BCEL wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von BCEL schneller wachsen werden als der Markt von US.

Hohe Wachstumseinnahmen: BCEL wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von BCEL in 3 Jahren voraussichtlich hoch sein wird

This company listing is no longer active

Atreca Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 24% to US$9.44

Price target increased to US$15.57

Price target decreased to US$16.63

Price target decreased to US$19.56

Price target decreased to US$25.33

Analysts update estimates

Recent updates

Atreca, Inc. Announces Resignation of Franklin Berger from the Board

Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL).

Atreca, Inc. Files Form 15

Atreca, Inc.(OTCPK:BCEL) dropped from S&P TMI Index

Atreca, Inc.(OTCPK:BCEL) dropped from NASDAQ Composite Index

Atreca, Inc. Receives Written Notification from Nasdaq Regarding Minimum Bid Requirement

New major risk - Financial position

Atreca, Inc. Announces Board Resignations

Insufficient new directors

Atreca, Inc. Announces Resignation of Herbert Cross, Chief Financial Officer

Atreca Receives Notice from the Nasdaq Stock Market

Atreca, Inc. Reduces its Workforce by Approximately 40%

New major risk - Revenue and earnings growth

Here's Why We're A Bit Worried About Atreca's (NASDAQ:BCEL) Cash Burn Situation

Atreca, Inc. Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors During Oral Abstract

Insufficient new directors

Price target decreased by 24% to US$9.44

Atreca, Inc. Announces the Appointment of Philippe Bishop, MD, as Chief Medical Officer

Can Atreca (NASDAQ:BCEL) Afford To Invest In Growth?

Price target increased to US$15.57

Atreca GAAP EPS of -$0.72 misses by $0.02

Atreca, Inc.(NasdaqGS:BCEL) dropped from Russell 2500 Index

Here's Why We're A Bit Worried About Atreca's (NASDAQ:BCEL) Cash Burn Situation

Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer

Price target decreased to US$16.63

Atreca, Inc. Announces Publication in PNAS Mobilization of Innate and Adaptive Antitumor Immune Responses by the RNP-Targeting Antibody ATRC-101

Atreca: Biotech With Promise Based On First Candidate ATRC-101

Atreca, Inc. Provides an Update on Its Preclinical Pipeline in Oncology

Founder notifies of intention to sell stock

Is Atreca (NASDAQ:BCEL) In A Good Position To Invest In Growth?

Price target decreased to US$19.56

Atreca: Overvalued, Then Undervalued, Now Under Pressure - Making The Buy Case

Founder notifies of intention to sell stock

Atreca: Safety Data Brought Down Stock

Is Atreca (NASDAQ:BCEL) In A Good Position To Invest In Growth?

Price target decreased to US$25.33

Atreca, Inc.(NasdaqGS:BCEL) dropped from Russell 2500 Growth Index

We Think Atreca (NASDAQ:BCEL) Can Afford To Drive Business Growth

Chief Scientific Officer has left the company

Atreca, Inc Announces Executive Changes

Chief Business Officer has left the company

New 90-day low: US$13.00

Need To Know: Atreca, Inc. (NASDAQ:BCEL) Insiders Have Been Buying Shares

Co-Founder notifies of intention to sell stock

New 90-day high: US$15.82

We Think Atreca (NASDAQ:BCEL) Can Afford To Drive Business Growth

Atreca EPS misses by $0.06

Director notifies of intention to sell stock

New 90-day high: US$15.79

New 90-day low - US$12.67

Analysts update estimates

New 90-day low - US$14.63

Atreca, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken